secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-122839
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus Q3 net loss $13.8M; CRB-701 dose escalation complete; cash $159.4M
-------------------------------------------------------------------------

- Net loss of $13.8M ($1.15/diluted share) vs $10.1M ($2.27) in Q3 2023; operating expenses up $6.0M to $15.5M.
- Cash, cash equivalents and investments $159.4M; expects to fund operations through Q3 2027.
- Raised $35.6M net proceeds via ATM program in Q3 by issuing 663,730 shares.
- Completed enrollment in CRB-701 dose escalation part of Phase 1; first data expected in Q1 2025.
- Final $11.8M loan payment made; loan fully paid off.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024122839/0000950170-24-122839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024122839/crbp-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer